Foghorn Therapeutics Inc.FHTXEarnings & Financial Report
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.
Revenue
$8.2M
Gross Profit
N/A
Operating Profit
$-18.5M
Net Profit
$-15.8M
Gross Margin
N/A
Operating Margin
-226.9%
Net Margin
-194.4%
YoY Growth
4.4%
EPS
$-0.25
Foghorn Therapeutics Inc. Q3 FY2025 Financial Summary
Foghorn Therapeutics Inc. reported revenue of $8.2M (up 4.4% YoY) for Q3 FY2025, with a net profit of $-15.8M (up 17.1% YoY) (-194.4% margin).
Key Financial Metrics
| Total Revenue | $8.2M |
|---|---|
| Net Profit | $-15.8M |
| Gross Margin | N/A |
| Operating Margin | -226.9% |
| Report Period | Q3 FY2025 |
Foghorn Therapeutics Inc. Annual Revenue by Year
Foghorn Therapeutics Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $30.9M).
| Year | Annual Revenue |
|---|---|
| 2025 | $30.9M |
| 2024 | $22.6M |
| 2023 | $34.2M |
| 2022 | $19.2M |
Foghorn Therapeutics Inc. Quarterly Revenue & Net Profit History
Foghorn Therapeutics Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $9.2M | +223.8% | $-21.7M | -234.3% |
| Q3 FY2025 | $8.2M | +4.4% | $-15.8M | -194.4% |
| Q2 FY2025 | $7.6M | +9.7% | $-17.9M | -237.3% |
| Q1 FY2025 | $6.0M | +17.9% | $-18.8M | -316.4% |
| Q4 FY2024 | $2.9M | -50.5% | $-19.5M | -682.9% |
| Q3 FY2024 | $7.8M | -55.3% | $-19.1M | -244.9% |
| Q2 FY2024 | $6.9M | +23.0% | $-23.0M | -333.6% |
| Q1 FY2024 | $5.0M | -4.9% | $-25.0M | -495.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.0M | $6.9M | $7.8M | $2.9M | $6.0M | $7.6M | $8.2M | $9.2M |
| YoY Growth | -4.9% | 23.0% | -55.3% | -50.5% | 17.9% | 9.7% | 4.4% | 223.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $255.0M | $328.6M | $308.4M | $284.0M | $258.7M | $226.2M | $205.0M | $198.1M |
| Liabilities | $352.5M | $342.9M | $336.7M | $329.5M | $320.3M | $302.9M | $294.6M | $306.6M |
| Equity | $-97.5M | $-14.3M | $-28.3M | $-45.5M | $-61.7M | $-76.7M | $-89.7M | $-108.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-29.3M | $-25.5M | $-21.0M | $-24.5M | $-24.0M | $-21.0M | $-18.9M | $-22.3M |